Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bristol Myers Squibb (NYSE: BMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings help investors understand how a global biopharmaceutical company in pharmaceutical preparation manufacturing manages its capital structure, reports financial results and communicates material events.
Recent Form 8-K filings from Bristol-Myers Squibb Company cover a range of topics. Some 8-Ks furnish quarterly earnings press releases and accompanying investor presentations, giving detail on financial performance and operating initiatives. Others describe the issuance of euro-denominated senior notes by a wholly owned Irish subsidiary, fully and unconditionally guaranteed by the company, including the terms of the notes, the governing indenture and the intended use of proceeds for tender offers and other corporate purposes. Additional 8-Ks outline cash tender offers for existing notes, early participation results, accepted amounts and pricing terms.
Filings also document corporate governance and executive matters, such as the departure of certain senior executives and related compensation arrangements, along with regular disclosures of dividend declarations. Regulation FD disclosures appear when the company posts investor presentations or updates on its website, and when it furnishes investor decks or webcasts tied to earnings calls and capital markets events.
On Stock Titan, these documents are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the significance of complex filings, from debt offerings and tender offers to earnings releases and Regulation FD presentations. Users can quickly see what each filing covers, identify items related to capital markets activity, dividends or governance, and then drill into the full text when deeper analysis is needed. This page is a practical starting point for reviewing Bristol Myers Squibb’s official disclosures that may affect BMY stock and related securities, including its listed notes and Celgene contingent value rights.
Bristol-Myers Squibb (BMY) filed an 8-K on 31-Jul-2025 to furnish, rather than file, its second-quarter 2025 earnings materials.
- Item 2.02: Exhibit 99.1 is the press release containing Q2-25 results.
- Item 7.01: Exhibit 99.2 is an investor presentation used for the 8:00 a.m. ET conference call.
- Both exhibits include non-GAAP figures with GAAP reconciliations; no financial metrics appear in the body of the 8-K itself.
- The furnished status limits Exchange Act §18 liability and prevents automatic incorporation into future filings unless specifically referenced.
- No other material transactions, governance changes or financing actions were disclosed.
The filing also lists NYSE-traded securities—common stock, 1.750 % notes due 2035, and Celgene CVRs—and contains standard emerging-growth-company and Regulation FD boilerplate.
Form 8-K – Item 5.02 (Departure of Certain Officers)
On 25 July 2025, Bristol-Myers Squibb Company (NYSE: BMY) reported that Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer & Head of Development, will step down from these roles effective 1 August 2025 and will fully exit the company on or before 1 November 2025. During the interim period he will act as an advisor.
Separation terms
- Cash severance governed by the U.S. Severance Benefits Plan.
- Pro-rated vesting of outstanding Market Share Units and Performance Share Units under the 2021 Stock Award & Incentive Plan.
- Prorated 2025 annual incentive under the Senior Executive Performance Incentive Plan.
No successor, strategic changes, or financial impact projections were disclosed. A related press release is furnished as Exhibit 99.1.